Cormorant Global Healthcare Master Fund, LP, 10% Owner, Director at Apellis Pharmaceuticals, Inc. (APLS), bought 3,473,925 shares at $14.00 ($15.0M) on 2017-11-13, disclosed to the SEC on 2017-11-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 2,402,497 | $0 | 0.0% |
| 2 | $14.00 | 1,071,428 | $15.0M | 100.0% |
| Total | $4.32 avg | 3,473,925 | $15.0M | 100% |
| Filing → |
| DRUG | BUY | 2024-10-17 | $6.4M | — | Filing → |
| CRBP | BUY | 2024-09-24 | $14.0M | — | Filing → |
| EYPT | BUY | 2024-04-22 | $21.0M | — | Filing → |